




UNIKLINIK
KÖLN

Häufigkeit und Prognose der symptomatischen Rückenmarkskompression bei Neuroblastom, Ergebnisse einer retrospektiven Analyse und Vorstellung einer internationalen Registerstudie

Thorsten Simon (Köln, Germany), Barbara Hero (Köln, Germany), Cathy Niemann (Köln), Shifra Ash (Petach-Tikva, Israel), Riccardo Haupt (Genova, Italy), Bruno De Bernardi (Genova, Italy), Maya Beck Popovic (Lausanne, Switzerland), Kathelijne Kraal (Amsterdam, The Netherlands), Dominique Plantaz (Grenoble, France), Toby Trahair (Sydney, Australia), Stefania Sorrentino (Genova, Italy), Giovanni Erminio (Genova, Italy)

Neuroblastoma – Spinal canal invasion



Retrospective analysis of NB90-NB2004 – Patients' characteristics

		symptoms of spinal cord compression		p value
		No [%] N=2481	Yes [%] N=122	
INSS-stage	1-3	51.8	71.3	<0.001
	4	37.0	20.5	
	4S	10.9	8.2	
Age at diagnosis	median (years)	1.28 yrs	0.74 yrs	0.001
Primary tumor site	neck	2.9	0.0	<0.001
	chest	12.2	38.5	
	abdomen	77.5	51.6	
	pelvis	2.3	6.6	
	tumor extending one cavity	4.0	3.3	
	tumor not detected	1.1	0.0	
	other	0.0	0.0	
MYCN status	Single copy	73.1	79.5	<0.001*
	Amplified	15.6	4.9	
	Not known	11.4	15.6	

Retrospective analysis of NB90-NB2004 – Early response


Time point	Symptoms	initial neuro- surgery group [%] n=52	initial chemo- therapy group [%] n=47	p value
early response to treatment	improved	69	64	0.767
	unchanged	23	26	
	deteriorated	2	4	
	no completely assessed	6	6	
at the end of risk adapted tumor treatment	improved	81	72	0.598
	unchanged	11	17	
	deteriorated	4	9	
	no completely assessed	4	2	

Retrospective analysis of NB90-NB2004 – Late effects

Symptoms		initial neuro- surgery group [%] n=52	initial chemo- therapy group [%] n=47	p value
any impairment		79	64	0.120
motor impairment	Level I	57	58	0.080
	Level II	6	19	
	Level III	17	17	
	Level IV	20	6	
	Level V	0	0	
bladder dysfunction		27	26	1.000
constipation		12	28	0.072
pain		6	4	1.000
sensory neuropathy		21	13	0.299
scoliosis		35	28	0.519
impaired growth		15	13	0.779



International NB-SCI Registry – Participating Countries by August 15, 2016





International NB-SCI Registry – Eligibility criteria

Inclusion criteria


- Diagnosis of peripheral neuroblastic tumour – PNT (neuroblastoma, ganglioneuroblastoma, ganglioneuroma)
- presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression)
- No previous chemotherapy, except steroids, in the last 6 months
- Age <18 years
- Minimal planned follow-up of 5 years
- Parent/patient written informed consent

Exclusion criteria

- Invasion of intervertebral foramina only



International NB-SCI Registry – Expected and observed recruitment rates





International NB-SCI Registry – Motor deficit vs treatment for SCI

Modification motor deficit at 1 - 2 mo.				
	Unchanged absent	Unchanged present	Improved/ Disappeared	All
Treatment	N (%)	N (%)	N (%)	N
Neurosurgery	1 (50)	0	1 (50)	2
Neurosurgery + Chemotherapy	1 (17)	2 (33)	3 (50)	6
Chemotherapy	10 (67)	0	5 (33)	15
Resection of extraspinal tumour	1 (100)	0	0	1
Total	13 (55)	2 (8)	9 (37)	24

P= 0.106



International NB-SCI Registry – Dokumentation

**CRF 1 a
REGISTRATION**

**CRF 1 b
SYMPTOME**

Schmerzen,
Dyspnoe,
Parästhesien,
Motorik,
Darmfunktion,
Blasenfunktion

**INITIALE
BILDGEBUNG
auf CD-ROM**

**CRF 2
SYMPTOME**

72 h, 1 Wo, 2 W, 4
Wo, 2 Mo nach
Therapiebeginn
(OP, Chemo oder
RT)

**CRF 3
FRONT-LINE
TREATMENT
und
BILDGEBUNG DES
BESTEN
ANSPRECHENS**

**CRF 4
SYMPTOME**

End of Treatment,
6 Monate, 1 Jahr,
2 Jahre, 3 Jahre, 4
Jahren, 5 Jahre
und 10 Jahre nach
Diagnose



International NB-SCI Registry –

System	Items
General	Upper motor deficit (ASIA)
	Lower motor deficit (ASIA)
	Pain (CTCAE)
	Dyspnea (CTCAE)
	Paresthesia (CTCAE)
Bowel	Fecal incontinence (CTCAE)
	Constipation (CTCAE)
Bladder	Urinary incontinence (CTCAE)
	Urinary retention (CTCAE)
Spine	Joint range of motion decreased, Cervical spine (CTCAE)
	Joint range of motion decreased, Lumbar spine (CTCAE)
	Scoliosis (CTCAE)
	Kyphosis (CTCAE)
	Lordosis (CTCAE)
	Other, specify

CRF 1 a
REGISTRATION

CRF 1 b
SYMPTOME

Schmerzen
Dyspnoe
Parästhesie
Motorik
Darmfunktion
Blasenfunktion

INITIALE
BILDGEBUNG
auf CD-ROM


Therapiebeginn
(OP, Chemo oder
RT)

BESTEN
ANSPRECHENS

2 Jahre, 3 Jahre, 4
Jahre, 5 Jahre
und 10 Jahre nach
Diagnose



International NB-SCI Registry – Datenfluss





**Vielen Dank für die
lückenlose Meldung
von Patienten mit
SCI bei
Neuroblastom**



Acknowledgement

Trial office Cologne

Frank Berthold
Barbara Hero
Diana Dvoraczek
Boris Decarolis
Martina Breuer
Monika Schmitz

Tumor bank and bone marrow lab Cologne

Heike Düren
Nadine Hemstedt
Witali Lorenz
Roswitha Schumacher
Anke Gradehandt
Henning Steinseifer

Research lab Cologne

Matthias Fischer
Carolina Rosswog
Jessica Theissen
Sandra Ackermann
Yvonne Kahlert
Anne Engesser
Andrea Krämer

Reference labs in Heidelberg, Stuttgart, and Zurich

Frank Westermann
Manfred Schwab
Freimut H. Schilling
Felix Niggli

German Children's Cancer Registry Mainz

Claudia Spix
Peter Kaatsch

Institut für Paidopathologie Kiel

Ivo Leuschner

Grants



Deutsche Leukämie Forschungshilfe



... and all patients, their
families, and hospitals